CD117 Expression Is a Sensitive but Nonspecific Predictor of <i>FLT3</i> Mutation in T Acute Lymphoblastic Leukemia and T/Myeloid Acute Leukemia

Hoehn, Daniela; Medeiros, L. Jeffrey; Chen, Su S.; Tian, Tian; Jorgensen, Jeffrey L.; Ahmed, Yasin; Lin, Pei

doi:10.1309/ajcpr3n3jmsylpfg

Cited by 50 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, T-ALL/ LBL with an ETP immunophenotype has a genetic profile more akin to normal hematopoietic and myeloid leukemic stem cells 33 and may carry FLT3-ITD mutation, a feature typically associated with AML. 34 TdT is normally expressed in committed T-lymphocytic progenitors. 35 TdT-negative T-ALL/LBL may be derived from an early stage of T precursors simply lacking TdT expression or from a later stage of precursors with a perturbed T-cell differentiation.…”

Section: Discussionmentioning

confidence: 99%

Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma

et al. 2013

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma

et al. 2013

Self Cite

View full text Add to dashboard Cite

“…Seven of 15 patients (47%) were positive for FLT3 mutations (mostly ITD), all of which were CD117 1 . 36 Array-based comparative genomic hybridization analysis in 12 patients with MPAL demonstrated that all patients had at least 1 abnormality, including deletions of CDKN2A, IKZF1, MEF2C, BCOR, EBF1, KRAS, LEF1, MBNL1, PBX3, and RUNX1. 27 …”

Section: Genetic Alterations In Mpalmentioning

confidence: 99%

How I treat mixed-phenotype acute leukemia

Wolach

Stone

2015

Blood

138

139

View full text Add to dashboard Cite

Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe this entity. MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 World Health Organization monograph on classification of tumors of hematopoietic and lymphoid tissues. In adult patients, MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities. No prospective, controlled trials exist to guide therapy. The limited available data suggest that an “acute lymphoblastic leukemia–like” regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended. The role of immunophenotypic and genetic markers in guiding chemotherapy choice and postremission strategy, as well as the utility of targeted therapies in non–Ph-positive MPALs is unknown.

show abstract

“…Mutations of genes typical for leukemic cells were described in 12/31 (39%) patients with MPAL in Chinese study 14 . FLT3 mutation was reported in 7/15 (45%) patients with T/myeloid MPAL, with internal tandem duplication being the mechanism in 6/7 (86%) cases 24 .…”

Section: Molecular Biologymentioning

confidence: 99%

Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment

Čerňan¹,

Szotkowski²,

Pikalova³

2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Mixed-phenotype acute leukemia (MPAL) is a heterogeneous group of hematopoietic malignancies in which blasts show markers of multiple developmental lineages and cannot be clearly classified as acute myeloid or lymphoblastic leukemias. Historically, various names and classifications were used for this rare entity accounting for 2-5% of all acute leukemias depending on the diagnostic criterias used. The currently valid classification of myeloid neoplasms and acute leukemia published by the World Health Organization (WHO) in 2016 refers to this group of diseases as MPAL. Because adverse cytogenetic abnormalities are frequently present, MPAL is generally considered a disease with a poor prognosis. Knowledge of its treatment is limited to retrospective analyses of small patient cohorts. So far, no treatment recommendations verified by prospective studies have been published. The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy. The establishment of cooperative groups and international registries based on the recent WHO criterias are required to ensure further progress in understanding and treatment of MPAL. This review summarizes current knowledge on the diagnosis, classification, prognosis and treatment of MPAL patients.

show abstract

CD117 Expression Is a Sensitive but Nonspecific Predictor of FLT3 Mutation in T Acute Lymphoblastic Leukemia and T/Myeloid Acute Leukemia

Cited by 50 publications

References 16 publications

Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma

Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma

How I treat mixed-phenotype acute leukemia

Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment

Contact Info

Product

Resources

About